Towards Healthcare Research & Consulting
US Oral Solid Dosage CDMO Market
Updated Date: 07 July 2026   |   Report Code: 6996

US Oral Solid Dosage CDMO Market Industry Outlook

According to Rohan Patil, who specializes in oral dosage formulations, CDMO services, and healthcare market intelligence, with 5+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. oral solid dosage CDMO market. The U.S. oral solid dosage CDMO market size was estimated at USD 14.38 billion in 2025 and is predicted to increase from USD 15.33 billion in 2026 to approximately USD 27.2 billion by 2035, expanding at a CAGR of 6.58% from 2026 to 2035. His analysis highlights growing complex drug formulations, generic drug products, and advanced manufacturing technologies. The research also examines the competitive strategies of key industry participants, including Catalent, Inc., Lonza Group AG, Thermo Fisher Scientific Inc., Piramal Pharma Solutions, Cambrex Corporation, and Recipharm AB, shaping the future of oral solid dosage CDMO in the U.S.

Last Updated : 07 July 2026 Category: Pharmaceuticals Insight Code: 6996 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • US Oral Solid Dosage CDMO Market Analysis, By Product Type
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO  Market Analysis, By Service Type
    • Market Size, Forecast & CAGR,By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By Therapeutic Area
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By Customer Type
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By End User
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By Drug Potency
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By Manufacturing Scale
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • US Oral Solid Dosage CDMO Market Analysis, By Release Profile
    • Market Size, Forecast & CAGR, By Product Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Product Type
      • By Service Type
      • By Therapeutic Area
      • By Customer Type
      • By End User
      • By Drug Potency
      • By Manufacturing Scale
      • By Release Profile
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • Catalent, Inc.
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • Aenova Group
    • Lonza Group AG
    • Cambrex Corporation
    • Thermo Fisher Scientific Inc.
    • Piramal Pharma Solutions
    • Recipharm AB

FAQ's

Answer : The U.S. oral solid dosage CDMO market growth USD 15.33 Bn in 2026 is supported by rising demand for specialized manufacturing technologies, generic drugs, and personalized medicine

Answer : The release profile segment is growing due to an increasing focus on improving bioavailability, reducing dosing frequency, minimizing side effects, and enhancing patient compliance

Answer : National Institutes of Health, FDA, WHO, PIB, CDC

Meet the Team

Rohan Patil is a seasoned market research professional with over 5+ years of focused experience in the healthcare sector, bringing deep domain expertise, strategic foresight, and analytical precision to every project he undertakes.

Learn more about Rohan Patil

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar